Shanghai Pharma to raise $1 billion-plus to support acquisitions war chest
This article was originally published in Scrip
Executive Summary
One of China's largest pharmaceuticals groups is planning to raise more than $1 billion through a public offering of shares in Hong Kong, with around half of the proceeds to be allocated to mergers and acquisitions.